Is Medivation Too Expensive?

In this video segment, Motley Fool health care bureau chief Brenton Flynn looks at Medivation (NASDAQ: MDVN  ) . Shares already have a lot of high expectations priced in, and the company's prostate cancer drug Xtadi sells at a 30% premium compared to competitor Zytiga from Johnson & Johnson. With similar efficacy, what will Medivation need to do to help justify the premium pricing of both its drug and stock?

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2191730, ~/Articles/ArticleHandler.aspx, 7/31/2014 5:16:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement